Available online on <u>www.ijtpr.com</u>

International Journal of Toxicological and Pharmacological Research 2024; 14(5); 188-192

Original Research Article

A Case Control Study Assessing the Heart Rate Variation between Smokers and Non-Smokers

Poonam Rani¹, Neera Kumari², Kumar Saurabh³

¹Tutor, Department of Physiology, SKMCH, Muzaffarpur, Bihar, India ²Assistant Professor and HOD, Department of Physiology, SKMCH, Muzaffarpur, Bihar, India ³Associate Professor, Department of Microbiology, IGIMS, Patna, Bihar, India

Received: 25-03-2024 / Revised: 20-04-2024 / Accepted: 24-05-2024

Corresponding Author: Dr. Kumar Saurabh

Conflict of interest: Nil

Abstract

Aim: To compare the heart rate variability between male heavy smokers and non-smokers

Materials and Methods: The SKMCH Department of Physiology at Muzaffarpur, Bihar, India, performed this case-control research. The Smoking Index: The index was developed by multiplying the average daily cigarette consumption by the years smoked. The amount of cigarettes is the average daily consumption during the last week. Light (Smoking index1-100), moderate (101-200), and heavy (>201) smokers were considered. This research comprised 50 healthy male heavy smokers and 50 non-smokers aged 20-50.

Results: Resting pulse rate and blood pressure were significantly greater in smokers compared to nonsmokers (p<0.05). Smokers had significantly lower levels of high frequency power in normalised unit values compared to non-smokers (p<0.05) in terms of total power (ms2) and high frequency power (ms2). Smokers had greater LH/HF ratios compared to non-smokers, with a significant difference (p<0.05). Smokers had significantly lower SDNN and RMSSD values compared to non-smokers (p<0.05).

Conclusion: Compared to non-smokers, those who smoke have less parasympathetic activity and more sympathetic activity. Therefore, they are more prone to cardiovascular disorders caused by autonomic dys-function, namely sympathetic overactivity, which is caused by smoking. Measurement of HRV may therefore serve as a screening tool for the early detection of ANS changes prior to the onset of clinical symptoms.

Keywords: Heart rate variability, Parasympathetic activity, Sympathetic activity, Smokers.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

The HRV is a non-invasive way to monitor the function of the autonomic nervous system (ANS), which is responsible for maintaining a balance between the parasympathetic and sympathetic nervous systems. Heart rate variability (HRV) analysis has become more popular as a method for evaluating cardiovascular health. Pathological disorders are generally linked to decreased parasympathetic activity and greater sympathetic dominance, which are both indicated by lower HRV. One of the leading causes of death worldwide, smoking has a negative impact on the heart's ability to pump blood and regulate its own heart rate. [1]

The risk of cardiovascular disease and death is significantly elevated among heavy smokers. Smoking impairs autonomic regulation of heart function due to endothelial dysfunction, inflammation, oxidative stress, and carbon monoxide, two of the hazardous components of tobacco smoke. Cigarette smoke contains the active ingredient nicotine, which raises blood pressure and heart rate by activating the release of catecholamines. Tobacco poisoning, including nicotine, alters the autonomic balance so that the sympathetic nervous system is more dominant, interfering with the regular fluctuation of heart rate. [2,3]

When comparing HRV in smokers and nonsmokers, researchers have shown that smokers often have lower HRV. If HRV drops below this level, it means autonomic function is weakened and the risk of cardiovascular disease is higher. For example, lower time-domain and frequencydomain HRV measurements are indicative of greater sympathetic activity and decreased parasympathetic activity in chronic smokers, according to the research. [4]

In addition, heart rate variability (HRV) analysis can pinpoint the first signs of cardiovascular failure in smokers. Reduced HRV may be used as a predictor for cardiovascular events in smokers since it occurs before clinical symptoms do. Contrarily, non-smokers often have elevated HRV, which is indicative of a more balanced autonomic system and reduced risk of cardiovascular disease. [5]

In order to better understand how long-term smoking affects autonomic function, this research will compare HRV in men who smoke heavily with those who do not. These distinctions help us comprehend the dangers of smoking to our cardiovascular systems and the need of quitting the habit for greater autonomic health and lower rates of cardiovascular disease.

Materials and Methods

For this case-control study, researchers spent a year at SKMCH's Department of Physiology in Muzaffarpur, Bihar, India. Multiplying the average daily cigarette smoking rate by the total number of years of smoking yielded the smoking index. Cigarette use during the last seven days is represented by the average daily cigarette consumption. A light smoker was defined as having a smoking index between 1 and 100, a moderate smoker as having an index between 101 and 200, and a heavy smoker as having an index more than 201.

Inclusion Criteria

• Healthy 50 male heavy smokers and 50 nonsmokers of the age group 20-50 years.

Exclusion Criteria

- Subjects with respiratory, cardiovascular diseases and cerebrovascular diseases.
- Subjects taking any drug modulating the autonomic nervoussystem.
- Obese and underweight subjects were excluded.

Before any subjects gave their written informed permission, they were told on the study's purpose. Name, age, sex, profession, and phone number were among the personally identifiable information gathered. Body mass index, weight in kilogrammes, and height in centimetres were the anthropometric variables assessed.[10] Measures taken generally prior to doing heart rate variability tests. It was recommended that individuals refrain from fasting and avoid consuming tea, coffee, and other liquids that might impact heart rate variability before the testing. Keep calm and collected throughout the exam; don't exercise too hard in the hour leading up to the study; don't smoke or chew tobacco; don't drink alcohol for at least that long; and have a good night's sleep the night before. Between 10 a.m. and 1 p.m., all analysis was conducted. The subject was allowed to lie down for fifteen minutes prior to the start of the test. We counted the pulse in the right radial artery for a whole minute. We used an aneroid sphygmomanometer and a stethoscope to take the patient's systolic and diastolic blood pressure readings on their right arm. In order to analyse HRV, the POLY-RITE -D system was used for recording of heart rate variability: The patient had a brief 5-minute continuous tracing of lead II electrocardiography (ECG) at a speed of 30 mm/sec using POLY-RITE-D. Low-frequency (LF) measurements were collected in the range of 0.04-0.15 Hz, while high-frequency (HF) measurements were taken in the range of 0.15-0.40 Hz.5

Software version 16.0 of SPSS was used for statistical analysis. This data was presented as the Mean (S.D.). Time domain HRV measurements included things like mean heart rate, standard deviation of normal-to-normal intervals (SDNN), and root mean square of successive differences (RMSSD).

Results

The research comprised a total of 100 participants, 50 of whom did not smoke (controls) and 50 of whom smoked (cases). In terms of age and basal mass index (BMI), the non-smokers had a mean of 30.23 (6.59) and the smokers of 30.9 (8.40), while the former had a value of 24.04 (3.20) and the latter of 23.58 (3.36). The values of resting pulse rate and blood pressure were significantly higher in smokers compared to non-smokers (p<0.05). Table 1.

Smokers had significantly lower total power (ms2), high frequency power (ms2), and high frequency power in normalised unit values compared to non-smokers (p<0.05). Megs of low-frequency power In comparison to non-smokers, smokers had a larger low frequency power in normalised unit, LF/HF ratio, and this difference was statistically significant (p<0.05). Table 2

In comparison to non-smokers, smokers had lower SDNN and RMSSD values, and this difference was statistically significant (p<0.05). Table 3

Table 1: Age, anthropometric and basal cardiovascular	narameters of smokers and non-smokers
Table 1. Age, antill opometric and basar cardiovascular	parameters of smokers and non-smokers

Parameters	Control (Non-smokers) (n=50)	Cases (smokers) (n=50)	P Value	Statistical significance
	Mean (S.D.)	Mean (S.D.)		
Age (in years)	30.23(6.59)	30.9(8.40)	0.69	NS
BMI	24.04(3.20)	23.58(3.36)	0.53	NS

(in kg/m2) Resting pulse rate	71.95(1.24)	72.62(1.46)	0.02*	S
(in beats/min) Resting- Systolic blood pressure (in mmHg)	117.4(3.82)	119.05(3.23)	0.04*	S
Resting- Diastolic blood pressure (in mmHg)	79.85(0.70)	80.9(2.51)	0.01*	S

*p value <0.05 is statistically significant

Table 2: Comparison of Frequency domain HRV parameters between smokers and non-smokers

HRV Parameters	Control	Cases	P Value	Statistical
	(Non-smokers)(n=50)	(smokers) (n=50)		significance
	Mean (S.D.)	Mean (S.D.)		
TP (ms2)	2947.47(2796.25	1972.83(1003.84)	0.04*	S
LF (ms2)	569.85(1276.12)	1001(185.61)	0.03*	S
LF (n.u.)	78.60(5.39)	102.575(44.55)	0.001**	HS
HF (ms2)	122.95(92.09)	84.92(9.95)	0.01*	S
HF (n.u.)	21.45(5.38)	17.4(5.43)	0.001**	HS
LF:HF	3.65(3.10)	5.45(1.51)	0.001**	HS

*p value <0.05 is statistically significant. **p value<0.001 is statistically highly significant;

Table 3: Comparison of Time domain HRV parameters between smokers and non-smokers

HRV Parameters	Control (Non-smokers) (n=50)	Cases (smokers) (n=50)	P Value	Statistical sig- nificance
	Mean (S.D.)	Mean (S.D.)		
SDNN (ms)	38.61 (13.96)	30.60 (3.81)	0.0001**	HS
RMSSD (ms)	58.55 (182.68)	18.10 (4.72)	0.0001**	HS

*p value<0.05 is statistically significant **p value<0.001 is statistically highly significant;

Discussion

In our research, we found that healthy male heavy smokers had considerably higher resting pulse rate and baseline blood pressure compared to non-smokers. George et al. also found that smokers' pulse rates were much higher than nonsmokers', which might be because of reduced baroreflex function. [6] People who smoke heavily show more sympathetic activity. Total power and SDNN in frequency domain analysis show general autonomic control. Heavy smokers had much lower overall power compared to nonsmokers in our research. Another finding by Ferdousi et al. is that overall power is lower in heavy smokers compared to non-smokers. This might be because to a reduction in vagal tone. [7] Less parasympathetic activity is indicated by this. Parasympathetic activity is indicated by a high frequency, measured in ms2 and normalised units. Heavy smokers had a much lower high frequency compared to non-smokers in our research. Lee as well as Chang et al. also found similar results. [8] On the other hand, Karakaya found that, in response to acute smoking, HF was much higher in smokers than in non-smokers. [9] This suggests that heavy smokers have less parasympathetic activity compared to those who don't smoke. Both parasympathetic and sympathetic activity are indicated by low frequency

(ms2 and normalised units). In our investigation, we found that heavy smokers had a much higher low frequency than non-smokers. The research conducted by Taralov et al. also found similar results. [10] This result is at odds with that of Lee and Chang et al., who discovered that LF was much lower in smokers than in nonsmokers. The results show that heavy smokers' sympathetic activity is higher than that of nonsmokers. The ratio of sympathetic to parasympathetic tone, or LF/HF, shows how well the two systems are balanced. Heavy smokers had a much higher LF/HF ratio than non-smokers, according to our research. Both Saini et al. and Doss et al. found something similar. [9,10] This suggests that heavy smokers have more sympathetic activity compared to non-smokers, as shown in references. [11,12] Ferdous et al. likewise found that heavy smokers had elevated LF, reduced HF, and an increased LF/HF ratio, same as the previous study. [13] Parasympathetic dominance is shown by SDNN in time domain analysis. Heavy smokers had a much lower SDNN than non-smokers in our research. In a similar vein, Barutcu et al. found that heavy smokers' vagal regulation of the heart was decreased during a parasympathetic manoeuvre. [14] The current study's SDNN values align with those of Cagirci et al. and Erdem et al.Results

show that heavy smokers have lower parasympathetic activity compared to non-smokers. [15,16] A parasympathetic dominance indicator is RMSSD. When comparing heavy smokers to non-smokers, we found that RMSSD was much lower in the former group. Alyan et al. also found something similar. [17] This suggests that heavy smokers have less parasympathetic activity compared to those who don't smoke. Urooj et al. found the same thing for RMSSD and SDNN. [18] The current research suggests that nicotine and other chemicals in cigarette smoke are responsible for the substantial alterations in autonomic systems seen in heavy smokers. The autonomic nervous system becomes unbalanced in smokers as a result of the effects of nicotine on the adrenal gland and autonomic ganglia, which in turn cause an increase in catecholamine release, stimulation of the muscle sympathetic nerve, and sensitivity of peripheral chemoreceptors. By acting on beta1 adrenergic receptors, an increase in sympathetic activity causes myocardial contraction, which in turn raises blood pressure and the heart rate. Additionally, it acts on alpha2 adrenoceptors, which raise the tone of the coronary blood arteries. Due to direct effects on the baroreflex centres in the brainstem, longterm nicotine users have diminished baroreceptor sensitivity and elevated sympathetic activity. Therefore, autonomic dysfunction in heavy smokers is suggested by the current study's findings.

Conclusion

Compared to non-smokers, those who smoke have less parasympathetic activity and more sympathetic activity. Cigarette smokers are at increased risk for cardiovascular disease due to autonomic dysfunction, namely sympathetic overactivity. So, taking HRV readings might be a way to screen for ANS changes before any symptoms show up in the body.

References

- 1. Rajbanshi S, Norhayati MN, Nik Hazlina NH. High-risk pregnancies and their association with severe maternal morbidity in Nepal: a prospective cohort study. PLoS One. 2020;15 (12).
- 2. Qiu H, Zhang H, Han DD, Derakhshandeh R, Wang X, Goyal N, et al. Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. Heart Rhythm. 2023;20(1):76-86.
- Kärkelä J, Tenhola M, Karjalainen P, Voutilainen A, Tulppo M, Perkiömäki J. Reduced heart rate variability in overweight adults with hypertension. J Clin Hypertens. 2021;23(5):10 30-1037.
- 4. Shi Y, Wu X, Yu Y, Liu X, Zhang Z, Fan J, et al. Association of long-term smoking and

smoking cessation with resting heart rate variability in middle-aged and older adults: a cross-sectional study. Front Public Health. 2022;10:826830.

- Wu T, Ding X, Chen S, Wu M, Zhang W. Influence of smoking and smoking cessation on cardiovascular risk factors: a prospective cohort study of Chinese male smokers. BMC Public Health. 2021;21(1):1851.
- 6. George Papathanasiou, Dimitris Georgakopoulos *et al.*. Effect of smoking on heart rate at rest and during exercise, and heartrate recovery, in young adults. Hellenic J Cardiol 2013;54:168-177
- Dr. Sultana Ferdousi. Impact of smoking status on autonomic functions assessed by spectral analysis of heart rate variability. I J of Clinical and Experimental Physiology. 2014; 1(1):57-62
- 8. Lee and Chang *et al.* The effects of cigarette smoking on aerobic and anaerobic capacity and heart rate variability among female university students. International J Womens Health 2013;5:667-679
- 9. Karakaya O, Baructcu I ,Kaya D, Esen AM, Saglam M, Melek M *et al.*. Acute effect of cigarette smoking on Heart Rate Variability.Angiology2007;58:620-4.
- 10. Zdravko Taralov, Peter Dimov, Kiril Terziyski, Ilcho Ilchev, Stefan Kostinev. The effect of smoking on the autonomic heart regulation in "Healthy" male smokers.I J of MAB.2015;21(1):718-721.
- 11. Doss SS, Anandhalakshmi S, Rekha K, Akhil AK. Effect of Smoking on Heart Rate Variability in Normal Healthy Volunteers. Asian Journal of Pharmaceutical and Clinical Research.2016;9(4):230-34.
- 12. Saini S, Saxena Y, Gupta R. Arterial Compliance and Autonomic Functions in Adult Male Smokers.J Clin Diagn Res. 2016;10(5) :12-16.
- 13. Mehboba Ferdous, Sultana Ferdousi. Acute impact of cigarette smoking on power spectrul measures of heart rate variability.J Bangladesh Soc Physiol.2018;13(1):8-12
- 14. Barutcu I, Esen AM, Kaya D, Turkmen M, Karakaya O, Melek M, *et al.*. Cigarette smoking and heart rate variability: Dynamic influence of parasympathetic and sympathetic maneuvers. Ann Noninvasive Electrocardiol 2005;10:324-9
- 15. Cagirci G, Cay S, Karakurt O, Eryasar N, Kaya V, Canga A, *et al.*. Influence of heavy cigarette smoking on heart rate variability and heart rate turbulence parameters. Ann Noninvasive Electrocardiol 2009;14:327-32
- Erdem A, Ayhan SS, Ozturk S, Ozlu MF, Alcelik A, Sahin S *et al.* Cardiac autonomic functions in healthy young smokers. Toxicol Ind Health. 2015;31(1):67-72.

- 17. Alyan O, Kacmaz F, Ozdemir O, Maden O, Topaloglu S, Ozbakir C, *et al.*. Effects of cigarette smoking on heart rate variability and plasma N-terminal pro-B-type natriuretic peptide in healthy subjects: Is there the relationship between both markers? Ann Noninvasive Electrocardiol 2008;13:137-44
- Mohammad Urooj, M.Pharm, Monika Tondon *et al.*. Reference range for time domain parameters of heart rate variability in Indian population and validation in hypertensive subjects and smokers. Int J Pharm Pharm Sci; 3(1):36-39.